期刊
HUMAN IMMUNOLOGY
卷 77, 期 9, 页码 791-799出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2016.01.002
关键词
Breast cancer; sHLA-G; Extracellular vesicles; Prognostic impact; Neoadjuvant chemotherapy
类别
资金
- IFORES, University of Duisburg-Essen [D/107-81080]
- Deutsche Krebshilfe [109816]
The non-classical human leukocyte antigen G (HLA-G) molecule and its soluble forms exert multiple immune suppressive regulatory functions in malignancy and in stem cells contributing to immune escape mechanisms. HLA-G can be secreted as free soluble HLA-G molecules or via extracellular vesicles (EVs). Here we evaluated these soluble HLA-G forms as prognostic marker for prediction of the clinical outcome of neoadjuvant chemotherapy (NACT) treated breast cancer (BC) patients. Plasma samples of BC patients procured before (n = 142) and after (n = 154) NACT were quantified for total soluble HLA-G (sHLA-G(tot)) and HLA-G levels in ExoQuick (TM) derived EV fractions (sHLA-G(EV)) by ELISA. The corresponding increments were specified as free sHLA-G (sHLA-G(free)). Total and free sHLA-G were significantly increased in NACT treated BC patients compared to healthy controls (n = 16). High sHLA-G(free) levels were exclusively associated to estrogen receptor expression before NACT. Importantly, high sHLA-G(EV) levels before NACT were related to disease progression and the detection of stem cell-like circulating tumor cells, but high sHLA-G(tree) levels indicated an improved clinical outcome. Thus, this study demonstrates for the first time that the different sHLA-G subcomponents represent dissimilar qualitative prognostic impacts on the clinical outcome of NACT treated BC patients, whereas the total sHLA-G levels without separating into subcomponents are not related to clinical outcome. (C) 2016 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据